NCT06198296View on ClinicalTrials.gov

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

PHASE1RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 10, 2025

Primary Completion Date

February 1, 2028

Study Completion Date

February 1, 2043

Conditions
HepatoblastomaHepatocellular CarcinomaWilms TumorMalignant Rhabdoid TumorYolk Sac TumorRhabdomyosarcomaLiposarcomaEmbryonal Sarcoma of Liver
Interventions
GENETIC

21.15.GPC3-CAR T cells

"Three different dosing schedules will be evaluated.~The following dose levels will be evaluated:~The following dose levels will be evaluated:~DL0: 3x10\^7/m2 DL1: 1x10\^8/m2 DL2: 3x10\^8/m2 DL3: 1x10\^9/m2"

Trial Locations (1)

77030

RECRUITING

Houston Methodist Hospital, Houston

All Listed Sponsors
collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

lead

Baylor College of Medicine

OTHER

NCT06198296 - Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells | Biotech Hunter | Biotech Hunter